All In Biotech

Drug Trial Radar · NCT00527683

Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees

Last checked: Nov 19, 2026Latest source record: Apr 11, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Apr 2007

Primary completion

Nov 2007

Study completion Nov 2007

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Catalyst Pharmaceuticals, Inc.
First posted
Sep 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of vigabatrin for the treatment of cocaine dependence, based on the twice-weekly qualitative urine toxicologies for cocaine. Based on two prior unblinded human studies and 15 years of animal studies, this 100 subject double- blind, randomized study is designed to show if with vigabatrin treatment but not placebo, even non-hospitalized cocaine dependent individuals with ready access to cocaine will become cocaine abstinent if they are self motivated to stop their cocaine habit. To accomplish this, cocaine dependent subjects will be randomly assigned to either a placebo or vigabatrin treatment group and treated for a nine week period. The primary hypothesis is that as compared to the placebo arm, the vigabatrin treatment arm will show a significant increase in the number of subjects who are abstinent for the final 3 weeks of the study.

Conditions

  • Cocaine Dependence

Interventions

  • VigabatrinDrug

    crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks

  • PlaceboDrug

    orange juice is administered twice daily in containers indistinguishable from the treatment arm.

  • Group therapyBehavioral

    Participants attend group sessions once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Three consecutive weeks of negative urine tests (benzoyl ecgonine) for cocaine use (no slips allowed).Time frame: These must be the last three weeks (7,8,9) of the trial.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinica Integral de Tratamiento Contra las Adicciones SA de CV

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.